Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sex-specific Dose Calculation of Contrast Agent in CT Examinations
NCT06965790Recruiting
- Sponsor
- Universitätsklinikum Augsburg
- Start
- Apr 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of iomeprol (2 arms), sponsored by Universitätsklinikum Augsburg. Primary endpoints: Sex-specific contrast difference in the vessels and organs at 1 year and Contrasting the organs after adjusting the application dose at 1 year. Started Apr 2025; status: recruiting.
02
Drugs
iomeprol
Beyond the preview
Go deeper on NCT06965790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06965790.